SCHEMBL25037237

SCHEMBL25037237

Cc1cc(C(F)(F)F)ccc1NC(=O)Cn1c(CCO)c(N2CCN(C(=O)OC(C)(C)C)CC2)c(=O)n2nc(Br)nc12

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ WRN Q14191 1/20 0.43
▸ MAPT P10636 2/20 0.35
▸ ENPP2 Q13822 1/20 0.34
▸ BACE1 P56817 4/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ P2RX7 Q99572 2/20 0.34
▸ HSD17B10 Q99714 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ ESR2 Q92731 1/20 0.33
▸ NPC1 O15118 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ NR2F2 P24468 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ GPR119 Q8TDV5 1/20 0.33
▸ MAPK8 P45983 1/20 0.32
▸ NOD2 Q9HC29 1/20 0.32
▸ NOD1 Q9Y239 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30039143 0.94 WRN (0.40) WRNMAPTENPP2BACE1ALDH1A1
SCHEMBL25035212 0.93 WRN (0.49) WRNMAPTENPP2BACE1ALDH1A1
SCHEMBL30038096 0.93 WRN (0.49) WRNMAPTENPP2BACE1ALDH1A1
SCHEMBL30038271 0.90 WRN (0.58) WRNENPP2BACE1HSD17B10NPSR1
SCHEMBL30039173 0.87 WRN (0.45) WRNMAPTENPP2BACE1ALDH1A1
SCHEMBL31500029 0.87 WRN (0.47) WRNMAPTENPP2BACE1ALDH1A1
SCHEMBL25036809 0.86 WRN (0.55) WRNMAPTBACE1ALDH1A1P2RX7
SCHEMBL31057730 0.86 WRN (0.55) WRNMAPTBACE1ALDH1A1P2RX7
SCHEMBL31499631 0.86 WRN (0.47) WRNMAPTBACE1P2RX7HSD17B10
SCHEMBL25035300 0.86 WRN (0.61) WRNMAPTENPP2ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230046859-A1 Bicyclic Compounds and their Uses NOVARTIS PHARMA AG (CH) 2023-02-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230046859-A1 Bicyclic Compounds and their Uses H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, F12 WRN 1829/4885MAPT 2519/4885ENPP2 2445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback